InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Scientific Advisory Board

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has formed a scientific advisory board (“SAB”). Initial board members include the following: Dr. Raphael Mechoulam from the Hebrew University in Israel; Dr. Kevin Tracey from Hofstra/Horthwell in the United States; Dr. Irene Tracey from the Oxford University in England; Dr. Chas Bountra, also from the Oxford University in England; and Dr. Sallie Lamb from Exeter University in England. “We believe this diverse, international and talented group will complement our scientific founders — Sir Marc Feldmann (Oxford, England), Drs. Larry Steinman (Stanford, USA), and Jagdeep Nanchahal (Oxford, England) — along with myself (Stanford, USA), to provide 180 Life Sciences with the collective vision capable of stewarding the companies pipeline towards commercial success,” said 180 Life Sciences chief scientific officer Dr. Jonathan Rothbard in the press release.

To view the full press release, visit https://ibn.fm/JARYa

About 180 Life Sciences Corp.

180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease — inflammation. The company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The company’s primary platform is a novel program to treat fibrosis using anti-TNF (“TNF”) (tumor necrosis factor). For more information about the company, visit www.180LifeSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at https://ibn.fm/ATNF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.